Use of CSF biomarkers in Alzheimer’s disease clinical trials

被引：0
|
作者：
K. Blennow
H. Zetterberg
机构：
[1] the Sahlgrenska Academy at Göteborg University,Clinical Neurochemistry Laboratory
[2] The Sahlgrenska Academy at Göteborg University,Clinical Neurochemistry Lab
[3] Sahlgrenska University Hospital,undefined
来源：
JNHA - The Journal of Nutrition, Health and Aging | 2009年 / 13卷
关键词：
Mild Cognitive Impairment; Lewy Body Dementia; BACE1 Inhibitor; Secretase Inhibitor; Mild Cognitive Impairment Case;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease
    Parnetti, Lucilla
    Chiasserini, Davide
    BIOMARKERS IN MEDICINE, 2011, 5 (04) : 479 - 484
  • [32] Use of Biomarkers in Clinical Trials of Alzheimer DiseaseFrom Concept to Application
    Liyong Wu
    Pedro Rosa-Neto
    Serge Gauthier
    Molecular Diagnosis & Therapy, 2011, 15 : 313 - 325
  • [33] Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective
    Hampel, H.
    Prvulovic, D.
    JOURNAL OF NUTRITION HEALTH & AGING, 2012, 16 (04) : 346 - 348
  • [34] Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI
    Caroli, Anna
    Prestia, Annapaola
    Wade, Sara
    Chen, Kewei
    Ayutyanont, Napatkamon
    Landau, Susan M.
    Madison, Cindee M.
    Haense, Cathleen
    Herholz, Karl
    Reiman, Eric M.
    Jagust, William J.
    Frisoni, Giovanni B.
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2015, 29 (02) : 101 - 109
  • [35] Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
    Kang, Ju-Hee
    Ryoo, Na-Young
    Shin, Dong Wun
    Trojanowski, John Q.
    Shaw, Leslie M.
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2014, 18 (06) : 447 - 456
  • [36] Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer's Disease
    Meredith, Jere E., Jr.
    Sankaranarayanan, Sethu
    Guss, Valerie
    Lanzetti, Anthony J.
    Berisha, Flora
    Neely, Robert J.
    Slemmon, J. Randall
    Portelius, Erik
    Zetterberg, Henrik
    Blennow, Kaj
    Soares, Holly
    Ahlijanian, Michael
    Albright, Charles F.
    PLOS ONE, 2013, 8 (10):
  • [37] Alzheimer CSF biomarkers in routine clinical setting
    Tabaraud, F.
    Leman, J. P.
    Milor, A. M.
    Roussie, J. M.
    Barriere, G.
    Tartary, M.
    Boutros-Toni, F.
    Rigaud, M.
    ACTA NEUROLOGICA SCANDINAVICA, 2012, 125 (06): : 416 - 423
  • [38] Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease
    Marie-Odile Habert
    Leonardo Cruz de Souza
    Foudil Lamari
    Nelle Daragon
    Serge Desarnaud
    Claude Jardel
    Bruno Dubois
    Marie Sarazin
    European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 : 589 - 593
  • [39] Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer's disease
    Habert, Marie-Odile
    de Souza, Leonardo Cruz
    Lamari, Foudil
    Daragon, Nelle
    Desarnaud, Serge
    Jardel, Claude
    Dubois, Bruno
    Sarazin, Marie
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (03) : 589 - 593
  • [40] Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease
    Herholz, Karl
    BIOMARKERS IN MEDICINE, 2012, 6 (04) : 431 - 439
12345